Testing Blood Glucose at the Bedside in a Chronic Care Hospital
|
|
- Melanie Morton
- 6 years ago
- Views:
Transcription
1 CHEMISTRY Robert M. Greendyke, MD F. Ronald Gifford, MT(ASCP) Testing Blood Glucose at the Bedside in a Chronic Care Hospital We can provide tests that are fast, inexpensive, or accurate. Pick two. Anonymous Most authors agree that bedside or point-of-care testing for blood glucose (BG) provides results quickly, usually in 5 to 8.5 minutes.1,2 Indeed, the most often-heard justification for this method is that it shortens turnaround times for reporting of urgently required results. Winkelman et al2 and Nosanchuk and Keefner,3 however, have demonstrated that pneumatic tube systems that rapidly transport specimens to the central laboratory offer a viable, cost-effective alternative when combined with special laboratory provisions that expedite reporting. A number of investigators have studied the costs of BG testing at the bedside and in the centralized laboratory for both large- and smallvolume applications. They concluded that bedside testing is substantially more costly in most settings. One of the authors found each test for BG cost $11.5 at the bedside whereas it cost $3.19 in the laboratory in a small Veterans Administration (VA) hospital.1 Winkelman and others reported bedside testing to cost $6.62 while laboratory testing cost $3.3 in a large teaching hospital.2 In a similar institution, LeeLewandrowski and others reported $4.19 for a bedside test and $3.84 for the test performed in the laboratory.4 (They did not include indirect costs for bedside BG testing while assessing central laboratory costs of 3%.) At the same time, Lee-Lewandrowski and colleagues separately calculated costs of $13.48 for bedside BG testing in an affiliated hospital. Somewhat disconcerting is the report from the College of American Pathologists' Q-Probe study on bedside BG testing5 analyzing data from 569 ABSTRACT A prospective study was carried out in a chronic care hospital to determine the clinical indications for testing blood glucose (BG) levels at the bedside and to assess the degree of correlation between the clinical impression of the patients' BG status and the results of these tests. Most (94%) BG tests performed on inpatients at the bedside were done to monitor routine treatment and did not require the rapid turnaround time afforded by this type of testing. Clinical estimation ofbg status was highly inaccurate, which presents the argument for routine monitoring but not for the immediate turnaround provided by this method. The cost ofbg testing at the bedside in low-volume settings is high, and the method is periodically unreliable. These disadvantages must be weighed against the undocumented advantages of the method: shorter hospital stays and more rapid stabilization ofbg levels. institutions. In this study, almost 9% of bedside results varied from those obtained in the central laboratory by more than 25%; 1.4% varied by more than 1 mg/dl (5.6 mmol/l) and several (.4%) by more than 2 mg/dl (11.1 mmol/l). In this study,5 14% to 16% of errors in bedside BG testing resulted in inappropriate treatment. The authors cited a report stating that 17 deaths and 871 patient injuries related to bedside BG testing had been reported to the Food and Drug Administration by March It seems fair to infer from the almost universal clinical acceptance and enthusiasm for bedside BG testing that this method has merits. Factual data to support this position are, however, currently unavailable.1'6'7 As Rainey and Jatlow have written, "We do not know whether bedside testing in the hospital, when compared to centralized testing with rapid turnaround, results in more rapid stabilization of glucose concentration or reduced hospital stay."7 Downloaded from JANUARY 1997 VOLUME 28, NUMBER 1 From the Pathology and Laboratory Medicine Service, Department of Veterans Affairs Medical Center, Canandaigua, NY. Presented at the ASCP/CAP Fall Meeting, New Orleans, September 18, Reprint requests to Dr Greendyke, Pathology and Laboratory Medicine Service, Department of Veterans Affairs Medical Center, 4 Fort Hill Ave, Canandaigua, NY LABORATORY MEDICINE
2 The study presented here was designed to gather information on the use of bedside BG No. of Tests Indication testing in a long-term1,621 Therapy management care VA hospital with Suspected hyperglycemia 55 emphasis on clinical indications for testing 34 Suspected hypoglycemia and correlations bebehavioral change 1 tween the clinical imunknown 5 pression of the patient's BG level and the results of bedside BG testing. Although the data do not bear directly on the merits of bedside BG testing, they do permit certain inferences about the monitoring of the type of diabetic patient population served and the unreliability of the clinical assessment of BG levels from subjective evaluation. TABLE 1. WHY CLINICIANS ORDERED BEDSIDE BLOOD GLUCOSE TESTS Plan of Study The study was conducted at the Department of Veterans Affairs Medical Center in Canandaigua, NY. The institution is a 66-bed chronic care facility with a predominantly geriatric and chronic psychiatric population. The center has no surgical, obstetric, or pediatric services; no emergency department; and an intensive care unit of only five beds. In this hospital, testing for BG levels has been conducted at the bedside for the past 5 years using the Boehringer-Mannheim Accu-Chek Ilm meter (Indianapolis). To operate this instrument, the nurse-operator must be credentialed, demonstrate proficiency quarterly, and be recertified Fig 1. Frequency distribution of 1,725 blood glucose test results obtained at the bedside on four clinical units during a period of 18 days. LABORATORY MEDICINE VOLUME 28, NUMBER 1 JANUARY 1997 Downloaded from annually. The performance of the instrument is checked weekly, and a laboratory technologist monitors quality control. The number of instruments in use and the number of operators certified is restricted on medical wards that use the instrument at a high rate. The prospective study was conducted on one acute-care and three intermediate-care medical units for 18 consecutive days, beginning March 18, No newly diagnosed cases of uncontrolled diabetes mellitus were in the study. For all orders for bedside BG testing during the study period, clinicians were required to state the indication for testing, eg, suspected hypoglycemia or hyperglycemia, management of therapy, behavioral change, etc. All orders were entered into the hospital's computerized central data management system with the test results and demographic information. At the conclusion of the study, the data were collected and subjected to review. Hospital policy requires that conventional laboratory analysis confirm all abnormal results of bedside BG testing (ie, less than 6 mg/dl [3.3 mmol/l] or greater than 4 mg/dl (22.2 mmol/l]). When conventional laboratory analysis was performed, the results were available for comparison. Results During the study, 1,725 bedside BG tests were performed on 6 patients. Each patient was subjected to an average of 29 tests; patients were tested 1 to 28 times. Excluding patients with 4-r
3 only one or two tests, 1,77 tests were performed on 48 patients. (A mean of 36 tests was performed per patient in this group.) A plot of the frequency distribution for the bedside BG testing results is shown in Fig 1. The reasons why practitioners ordered the tests are shown in Table 1. The indication listed most often (94%) was management of treatment. Particular attention was paid to correlation between patients with clinically suspected hypoglycemia or hyperglycemia or with clinically unexplained behavioral change and the results of the bedside BG testing. Results are shown in Table 2, where it is apparent that the clinical suspicion of possible hypoglycemia was confirmed in only 24% of cases. The suspicion of possible hyperglycemia was confirmed for 69% of patients; 13% of patients had BG levels of greater than 4 mg/dl (22.2 mmol/l). Only 1 of 1 patients whose behavioral change was evaluated was found to have abnormal BG levels. Data regarding patients who were hypoglycemic or hyperglycemic when tested at the bedside correlated with their clinicians' impressions are presented in Table 3. Clinicians suspected hypoglycemia in only 17% of patients found hypoglycemic and suspected hyperglycemia in only 5% of patients found with hyperglycemia. In light of the potential clinical consequences of inaccurate results and the reportedly low 5 but definite occurrence of such errors in BG testing at the bedside, the results were examined to determine how often abnormal bedside BG testing results were confirmed immediately by laboratory testing. Despite a hospital rule requiring such confirmation, only 52 (33%) of 16 abnormal test results were verified. Of the 27 confirmed tests reporting BG levels of greater than 4 mg/dl, 1 (37%) of 27 were in error by more than 15%; such patients were not as hyperglycemic as the bedside results indicated. Of 15 results of BG levels of less than 6 mg/dl, 8 (53%) were in error by more than 25% TABLE 2. CLINIC AL IMPRE! 5SION OF GLUCOSE Al 3NORMALITY VS BEDSIDE BLI DOD GLUC OSE TEST RESULTS Clinical Impression Hypoglycemia (N=34) Hyperglycemia (N=55) Blood Glucose Level (mg/dl) <6 >6 >4 <4 >2 <2 No. of Patients TABLE 3. CORRELATION BETWEEN CLINICAL IMPRESSION AND ABNORMAL BLOOD GLUCOSE RESULTS Blood Glucose Level < 6 mg/dl (N=58) Hypoglycemia clinically suspected 1 Patients Hypoglycemia not clinically suspected 48 Patients Blood Glucose Level > 4 mg/dl (N=94) Hyperglycemia clinically suspected Hyperglycemia not clinically suspected A secondary goal of the study was to see what impact the introduction of bedside BG testing had on glucose testing in the laboratory (see Fig 2). The number of BG tests performed at the bedside doubled between 1992 and 1995, while the length of patient stay decreased by 17%. The volume of BG tests in the laboratory did not change. Thus, the postulated savings in labora tory testing of BG levels offered as an argument yf * & # # N c^ & & J? Blood Glucose Levels Tested at the Bedside ( 1 ) Blood Glucose Levels Tested in the Laboratory < 1 ) Cumulative Patient Days ( 1") 5 Patients 89 Patients Fig 2. Length of patient stay, glucose tests performed in the laboratory, and blood glucose testing performed at the bedside on four clinical units, Note: bedside testing began in 199. (1995 data: 9 months annualized.) c o 8» u e 3 E E o i 1 i Downloaded from JANUARY 1997 VOLUME 28, NUMBER 1 LABORATORY MEDICINE
4 for bedside BG testing has not materialized, nor do these data support the claim that the nationwide decrease in patient bed days can be attributed to BG testing at the bedside. Discussion Previous work from our institution 1 has shown that a bedside BG test costs the facility roughly three times as much as conventional laboratory glucose determination ($11.5 vs $3.19). With a modest annual volume of 6, tests, our institution's costs approximate $69, for testing BG at the bedside. The cost is wholly incremental, inasmuch as the volume of plasma glucose testing in the laboratory has not been reduced since bedside BG testing was introduced to this facility 5 years ago. Similar observations have been made previously by Lee-Lewandrowski and others. 4 Although $69, seems a modest sum by current standards, this figure becomes impressive when multiplied by the thousands of institutions testing BG at the bedside. Justifications for expenditures of this magnitude are required, but as pointed out by several authors, 5 ' 6 few factual data have been provided to demonstrate improved patient outcomes or decreased hospital stay. The usual arguments in favor of testing BG at the bedside focus on the rapidity with which test results are available. Great variability in laboratory test turnaround time arguably exists (partially because the way to determine the beginning and ending of turnaround time varies), yet a survey of 365 hospital laboratories conducted in 1993 reported a mean turnaround time of 76 minutes for routine laboratory testing for glucose. 8 Improvements, such as transporting specimens by pneumatic tubes, computerized reporting, specimen bar-coding, and improved automation were among factors cited in reducing turnaround time for routine testing by half between 198 and Winkelman and others 2 have achieved remarkable turnaround times for stat glucose tests in a major teaching hospital, reducing the mean turnaround time to 9.5 minutes. Because this method's cost-effectiveness and benefits to the patient have not been demonstrated, the authors have tried to obtain applicable data by indirect means. An attempt was made to find out why each BG test was done at the bedside. Clearly, allowances must be made for inaccurate orders by clinicians, but the data suggest two conclusions. First, management of therapy (ie, adjustment of insulin dosage) was the most common indication, and second, the clinical impression of the patient's BG status poorly correlated with the test results. It may not be appropriate to generalize about indications for bedside BG testing from the experience in a geriatric, chronic care institution to all hospitals. At least in this facility, however, it seems reasonable to say that even an hour's delay in the adjustment of daily or twice-daily insulin orders is not critical in most cases. The fact that 36 tests were performed on the average patient over 18 days, roughly one test every three days, strongly suggests that BG testing was performed at the bedside usually to monitor insulin administration, not to manage uncontrolled diabetic ketoacidosis. The greatest usage was for a single patient who had 28 tests in 18 days. The urgency of much of our bedside BG testing thus comes into doubt. The inability of our clinical staff to predict BG levels on subjective grounds is understandable but also argues for regular BG monitoring. Although the studied population is small, the clinical suspicion of either hypoglycemia or hyperglycemia was incorrect in the great majority of cases (74 of 89 instances). Conversely, hypoglycemia or hyperglycemia was present in 152 cases but suspected in only 15. No one would argue reasonably that suspected abnormalities in BG levels should not be confirmed at once, but the bulk of cases of severely elevated or decreased BG were not clinically suspect. This being the case, regular assessment is clearly needed, if for no other reason. A question could be raised, however, about whether bedside BG testing is the proper vehicle for routine inhospital monitoring. Point-of-care testing frequently is justified in terms of potentially reducing length of the patient's stay and faster clinical decision-making as a result of reduced turnaround time. 4 Yet a recent study by Tsai and others in a large institution failed to show major benefits even in the emergency room setting. 9 The authors found that point-of-care testing for a seven-analyte chemistry panel and for a complete blood count would have resulted in earlier therapeutic action in only 19% of emergency-room patients studied. Further, treatment of three fourths of these patients required an additional step, such as a consultation or computerized tomography scan that lengthened the patients' stay. Downloaded 66 from LABORATORY MEDICINE VOLUME 28, NUMBER 1 JANUARY 1997
5 CYTOSPIN 3 Finally, the authors remain concerned about the potential for substantial error in bedside BG testing results, as documented by the Q-Probe study reported by Jones5 and confirmed in the present work. Such errors have been shown to be more frequent in the case of inexperienced or infrequent users of the test instruments. Errors of 1 to 2 mg/dl ( mmol/l) occur in reported values;5 mistakes in reports of hypoglycemia were common in our study. When the therapeutic aim of diabetes control is rigid management of blood sugar levels, such errors are unacceptable, if not life-threatening. It could be argued that complications engendered by incorrect bedside BG testing results easily could nullify the postulated benefits of rapid turnaround times in shortening length of patient stay. More work is clearly needed to justify the expense and to prove the clinical benefits of the surge of bedside testing before even greater expansion of the concept is embraced. In the meantime, rigid attention to performance monitoring of the bedside BG testing remains essential. Conclusion In the authors' institution, clinical assessment of patients' BG status at extreme levels poorly correlates with the results of bedside BG testing. Most bedside BG testing at that institution is performed for nonemergent, routine monitoring, which can be accomplished more accurately and less expensively using conventional testing in the laboratory CYTOCENTRIFUGE The Pathologist's Choice For Monolayer Cell Preparation LID STAYS LOCKED UNTIL PROGRAM COMPLETION SEALED HEAD FOR SAFETY APPROVED SPEED AND TIME REMAINING DISPLAY LOW, MEDIUM AND HIGH ACCELERATION RATES 9 PROG MEMORY References 1. Grecndykc RM. Cost analysis: bedside blood glucose testing. Am I Clin Pathol. 1992;97: Winkelman JW, Wybenga DR, Tanasijevic MJ. The fiscal consequence of central versus distributed testing of glucose. ClinChem. 1994;4: Nosanchuk IS, Keefner R. Cost analysis of point-of-care laboratory testing in a community hospital. Am J Clin Pathol. 1995;13: Lee-Lewandrowski E, Laposata M, Eschenbach K, et al. Utilization and cost analysis of bedside capillary glucose testing in a large teaching hospital: implications for managing point of care testing. Am ) Med. 1994;97: Jones BA, Bachner P, Howanitz PJ. Bedside glucose monitoring: CAP Q-probe study of the program characteristics and performance in 65 institutions. Arch Pathol Lab Med. 1993;117: Bickford GR. Decentralized testing in the 199s. A survey of United States hospitals. Clin Lab Med. 1994;14: Rainey PM, Jatlow P. Monitoring blood glucose meters. Am ] Clin Pathol. 1995;13: Editorial. 8. Jahn M. Turnaround time: part I. MLO. 1993;25: Tsai WW, Nash DB, Seamonds B, Weir GT. Point of care versus central laboratory testing: an economic analysis in an academic medical center. Clin Ther. 1994;16: New Meyafunnels Now prepare samples of up to 6 ml per chamber in your Cytospin. Call For a free sample. HWTTTM LXiPSHAW A LIFE SCIENCES INTERNATIONAL COMPANY US CUSTOMERS CALL: FAX: (412) EXPORT CUSTOMERS CALL: (412) FAX: (412) YOUR SINGLE JANUARY 1997 Downloaded from SOURCE FOR VOLUME 28, NUMBER 1 PATHOLOGY LABORATORY MEDICINE
Assessment of a Critical Limit Protocol for Point-of-Care Glucose Testing
CLINICAL CHEMISTRY Original Article Assessment of a Critical Limit Protocol for Point-of-Care Glucose Testing GIFFORD LUM, MD A critical limit protocol requiring that all point of care glucose meter readings
More informationCAP Laboratory Improvement Programs. Comparative Analytical Costs of Central Laboratory Glucose and Bedside Glucose Testing
CAP atory Improvement Programs Comparative Analytical Costs of Central atory Glucose and Bedside Glucose Testing A College of American Pathologists Q-Probes Study Peter J. Howanitz, MD; Bruce A. Jones,
More informationGLYCEMIC CONTROL SURVEY
GLYCEMIC CONTROL SURVEY Objective: To gain an understanding of the current state of glycemic control (ie, intensive insulin therapy and frequent blood glucose testing) protocol use in hospital inpatients.
More informationDetermination of Delay in :flirn Around Time (TAT) of Stat Tests and its Causes: an AKUH Experience
Determination of Delay in :flirn Around Time (TAT) of Stat Tests and its Causes: an AKUH Experience F. Bilwani,I. Siddiqui,S. Vaqar ( Section of Chemical Pathology, Department of Pathology, Aga Khan University
More informationIt s Just a Waived Glucose, Isn t It?
It s Just a Waived Glucose, Isn t It? What Is the Next Step? Becky Damiani, MT (ASCP), Senior Inspection Specialist Laboratory Accreditation Program Objectives Understand the CLIA requirements surrounding
More informationGLYCEMIC CONTROL SURVEY
GLYCEMIC CONTROL SURVEY Objective: To understand how the results of the NICE-SUGAR study (The NICE-SUGAR Study Investigators, "Intensive Veruss Conventional Glucose Control in Critically Ill Patients",
More informationCAP Laboratory Improvement Programs. Utility of Repeat Testing of Critical Values. A Q-Probes Analysis of 86 Clinical Laboratories
CAP Laboratory Improvement Programs Utility of Repeat Testing of Critical Values A Q-Probes Analysis of 86 Clinical Laboratories Christopher M. Lehman, MD; Peter J. Howanitz, MD; Rhona Souers, MS; Donald
More informationLaboratory Results Timeliness as a Quality Attribute and Strategy
Laboratory Results Timeliness as a Quality Attribute and Strategy Joan H. Howanitz, MD, and Peter J. Howanitz, MD Key Words: Turnaround time; Strategy; Quality improvement Abstract Although timeliness
More informationMARSHALLTOWN MEDICAL & SURGICAL CENTER Marshalltown, Iowa
MARSHALLTOWN MEDICAL & SURGICAL CENTER Marshalltown, Iowa CARE OF PATIENT POLICY & PROCEDURE Policy Number: 4:10 Subject: Policy: Glucose Monitoring (Accuchek) Nursing department staff and laboratory staff
More informationCAP Laboratory Improvement Programs. Clinical Consequences of Specimen Rejection
CAP Laboratory Improvement Programs Clinical Consequences of Specimen Rejection A College of American Pathologists Q-Probes Analysis of 78 Clinical Laboratories Donald S. Karcher, MD; Christopher M. Lehman,
More informationc onsensus Statement on
c onsensus Statement on Self-Monitor ing of Blood Glucose Self-monitoring of blood glucose (SMBG) has become a major adjunct to the care of individuals with diabetes mellitus in the past decade. It is
More informationBLOOD GLUCOSE METER TEST STRIP STEP THERAPY CRITERIA
BLOOD GLUCOSE METER TEST STRIP STEP THERAPY CRITERIA Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan.
More informationDIABETES BLOOD GLUCOSE MONITORING AT HOME (ADULTS)
Type 2 Diabetes DIABETES BLOOD GLUCOSE MONITORING AT HOME (ADULTS) Clinical Guideline Self-monitoring of blood glucose (SMBG) should be considered but not be routinely offered for adults with type 2 diabetes
More informationTechnical Evaluation of Five Glucose Meters With Data Management Capabilities
Clinical Chemistry / LABORATORY EVALUATION OF GLUCOSE METERS Technical Evaluation of Five Glucose Meters With Data Management Capabilities Jeffrey]. Chance, PhD, Dai J. Li,MD, PhD, Kerrie A. Jones, MS,
More informationSUPPLEMENTARY DATA. Supplementary Methods
Supplementary Methods Chronic kidney disease stage 4 or 5 Current diabetic foot with ulcer, soft tissue infection or necrosis Unstable angina, myocardial infarction, or cerebrovascular accident over the
More informationFDA Perspective - Public Health Notification: Potentially Fatal Errors with GDH-PQQ Glucose Monitoring Technology Courtney C. Harper, Ph.D.
FDA Perspective - Public Health Notification: Potentially Fatal Errors with GDH-PQQ Glucose Monitoring Technology Courtney C. Harper, Ph.D., Director, Division of Chemistry and Toxicology Devices Office
More informationYour pet s diabetes is manageable
BLOOD GLUCOSE MONITORING SYSTEM Your pet s diabetes is manageable Treatment and Monitoring Plan for: Pet s Name: Clinic Name: Primary Vet: Clinic Phone No.: Clinic Email: Emergency Phone No: Today s Date:
More informationDIABETES BLOOD GLUCOSE MONITORING AT HOME (ADULTS)
DIABETES BLOOD GLUCOSE MONITORING AT HOME (ADULTS) Type 2 Diabetes Clinical Guideline Self-monitoring of blood glucose (SMBG) should be considered but not routinely offered for adults with type 2 diabetes
More informationMore about inferential control models
PETROCONTROL Advanced Control and Optimization More about inferential control models By Y. Zak Friedman, PhD Principal Consultant 34 East 30 th Street, New York, NY 10016 212-481-6195 Fax: 212-447-8756
More informationHEALTH PROFESSIONAL v SANOFI
CASE AUTH/3062/8/18 HEALTH PROFESSIONAL v SANOFI Toujeo leaflet A consultant physician complained about a six-page A5 gate-folded leavepiece produced by Sanofi. The leavepiece related to Toujeo (insulin
More informationPosition Statement of ADA / EASD 2012
Management of Hyperglycemia in Type2 Diabetes: A Patient- Centered Approach Position Statement of ADA / EASD 2012 Cause of : Type 2 diabetes Cardiovascular disorders Blindness End-stage renal failure Amputations
More informationAnalysis of Turnaround Time by Subdividing Three Phases for Outpatient Chemistry Specimens
144 Available online at www.annclinlabsci.org Annals of Clinical & Laboratory Science, vol. 39, no. 2, 2009 Analysis of Turnaround Time by Subdividing Three Phases for Outpatient Chemistry Specimens Hee-Jung
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE TREATMENT OF HYPERGLYCEMIA - ADULT SCOPE Provincial: Acute Care APPROVAL AUTHORITY Clinical Operations Executive Committee SPONSOR Diabetes, Obesity & Nutrition Strategic Clinical Network PARENT
More informationAdvances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the US FDA estimated
More informationKey Elements in Managing Diabetes
Key Elements in Managing Diabetes Presentor Disclosure No conflicts of interest to disclose Presented by Susan Cotey, RN, CDE Lennon Diabetes Center Stephanie Tubbs Jones Health Center Cleveland Clinic
More informationDIABETES BLOOD GLUCOSE MONITORING AT HOME (ADULTS)
Type 2 Diabetes DIABETES BLOOD GLUCOSE MONITORING AT HOME (ADULTS) Clinical Guideline Self-monitoring of blood glucose should be offered to all newly diagnosed type 2 diabetic patients as an integral part
More informationQuicker Diagnostic Testing of Cardiac Conditions in the ER
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/quicker-diagnostic-testing-of-cardiac-conditions-inthe-er/3630/
More informationVANDERBILT UNIVERSITY MEDICAL CENTER MULTIDISCIPLINARY SURGICAL CRITICAL CARE TRAUMA INTENSIVE CARE UNIT GLYCEMIC CONTROL PROTOCOL
VANDERBILT UNIVERSITY MEDICAL CENTER MULTIDISCIPLINARY SURGICAL CRITICAL CARE TRAUMA INTENSIVE CARE UNIT GLYCEMIC CONTROL PROTOCOL Background: For some time, the presence of diabetes and hyperglycemia
More informationQuality Specifications for POCT
Quality Specifications for POCT the patient journey perspective Christopher P Price Department of Clinical Biochemistry, University of Oxford, Oxford, UK Quality Specifications fit-for-purpose QUALITY
More informationManagement of Central Venous Access Devices. Blood Glucose Monitoring
Management of Central Venous Access Devices Blood Glucose Monitoring Purpose To provide education on the standard of care regarding the use and monitoring of the Accu- Chek Blood glucose machine, including
More informationInpatient Insulin: A Team Approach
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/inpatient-insulin-a-team-approach/3763/
More informationMARSHALLTOWN MEDICAL & SURGICAL CENTER Marshalltown, Iowa
MARSHALLTOWN MEDICAL & SURGICAL CENTER Marshalltown, Iowa CARE OF PATIENT POLICY & PROCEDURE Policy Number: 4:10 Subject: Policy: Glucose Monitoring (Accuchek) Nursing department staff and laboratory staff
More informationDIABETES MANAGEMENT DISCHARGE COMMUNICATION (DM-DC) AUDIT TOOL
DIABETES MANAGEMENT DISCHARGE COMMUNICATION (DM-DC) AUDIT TOOL Facility: Date: Data Collector s name: Email/Phone: Purpose: To evaluate your facility practices regarding communication of requisite diabetes
More informationNational Diabetes Inpatient Audit (NaDIA) 2016
National Diabetes Inpatient Audit (NaDIA) 2016 DIABETES A summary report for people with diabetes and anyone interested in the quality of care for people with diabetes when they stay in hospital. Based
More informationSetting The study setting was hospital. The economic study was carried out in Australia.
Economic evaluation of insulin lispro versus neutral (regular) insulin therapy using a willingness to pay approach Davey P, Grainger D, MacMillan J, Rajan N, Aristides M, Dobson M Record Status This is
More informationHypoglycemia Reduction STARTER PACK WEBINAR #1
Hypoglycemia Reduction STARTER PACK WEBINAR #1 Why is it important to reduce hypoglycemia? Why Hypoglycemia Reduction? Key Statistics Overall 29% reduction in ADEs since 2010 Hypoglycemia still occurs
More informationDiabetes Devices Workshop Angela Aldrich, PharmD, PhC April Mott, PharmD, PhC, BCPS Presbyterian Medical Group 28 January 2018
Diabetes Devices Workshop Angela Aldrich, PharmD, PhC April Mott, PharmD, PhC, BCPS Presbyterian Medical Group 28 January 2018 Pumps & Sensors & Meters, Oh My! A Tale of Two Meters Technology for glucometers
More informationZACHARY COMMUNITY SCHOOLS
PARENTAL CONSENT/ RELEASE OF INFORMATION/ AND STUDENT WITH DIABETES CONTRACT Student s Name D.O.B. Parent/Guardian Home Phone # Work/Cell Phone # School Teacher Grade Physician Office # Fax # 1. I give
More informationWe know these take time to gather, so please plan ahead!
CDL AND INSULIN CHECKLIST Are you a CDL holder who uses insulin for diabetes? As of November 2018, you can get certified to drive faster, with no waiver application process! Please bring all of the following:
More informationAbbott PXP Glucose Meters Resource: Lin Gustafson, MT(ASCP) Point of Care Coordinator, Laboratory
Abbott PXP Glucose Meters 2015 Resource: Lin Gustafson, MT(ASCP) Point of Care Coordinator, Laboratory Objectives After you complete this Computer-Based Learning (CBL) module, you should be able to: Explain
More informationA Children s Bedtime Story
A Children s Bedtime Story Setting: University Medical Center, Big Town, USA Scenario: 0500, last admission of the night, 10 previous admissions, all tucked in for the night Patient: 75 year old male with
More informationAviva Combo BLOOD GLUCOSE METER. Advanced Owner s Booklet for Self-Testing Only
Aviva Combo BLOOD GLUCOSE METER Advanced Owner s Booklet for Self-Testing Only Before You Start Testing About the meter and test strips Carefully read and follow the instructions in the Getting Started
More informationNICU Glucose Management AKA The Insulin Protocol
NICU Glucose Management AKA The Insulin Protocol Laurie Love, APRN, CNP, CPS Jennifer Rivera, APRN, CNS Background Insulin causes about 10-12 cases of hypoglycemia per year in the NICUs at Children s,
More informationManaging Diabetes for Improved Health and Economic Outcomes
Managing Diabetes for Improved Health and Economic Outcomes Based on a presentation by David McCulloch, MD Presentation Summary The contribution of postprandial glucose to diabetes progression and diabetes-related
More informationHospital Liability for Suicide: A Regional Survey
Hospital Liability for Suicide: A Regional Survey PAUL F. DON E. I ntrod uction SLAWSON, M.D. and FLINN, M.D.* When a hospital is sued following a patient suicide, the usual claim is wrongful death. An
More informationEvaluation Models STUDIES OF DIAGNOSTIC EFFICIENCY
2. Evaluation Model 2 Evaluation Models To understand the strengths and weaknesses of evaluation, one must keep in mind its fundamental purpose: to inform those who make decisions. The inferences drawn
More informationKeywords diabetes software, insulin, self-management, self-monitoring of blood glucose, SMBG
557188DSTXXX10.1177/1932296814557188Journal of Diabetes Science and TechnologyHinnen et al research-article2014 Original Article Use of Diabetes Data Management Software Reports by Health Care Providers,
More informationResearch Dissemination and Impact: Evidence from Web Site Downloads
Research Dissemination and Impact: Evidence from Web Site Downloads Lee Pinkowitz Georgetown University G-04 Old North Washington, DC 20057 Phone: (202) 687-2689 Fax: (202) 687-4031 Pinkowitz@msb.edu Abstract:
More informationAdvances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Insulin pump use: ~ 20% - 30% of patients with T1DM < 1% of insulin-treated patients with T2DM 2007 FDA estimates ~375,000 insulin pumps for
More informationApril Dear (Editor):
April 2014 Dear (Editor): Registered Dietitians (RD) play an integral role in patient care in the medical intensive care unit. RD s have increased knowledge in blood glucose control and reducing adverse
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA151 Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus This guidance was issued in
More informationPlug-and-play goes online
The next-generation Accu-Chek T Smart Pix software Plug-and-play goes online Proven tools for efficient and effective diabetes management 1 even for patients who are not in your office How many of these
More informationALL orders are active unless: 1. Order is manually lined through to inactivate 2. Orders with check boxes ( ) are unchecked
Available at: BMC-B BMC-D BMC-N BMC-S Condition/Status ***(NOTE)***For purpose of this DKA Regimen, DKA is considered clear only when the CO2 is GREATER than 18 meq/l and the anion gap is LESS than 12
More informationContractor Name: Novitas Solutions, Inc. Contractor Number: Contractor Type: MAC B. LCD ID Number: L34834 Status: A-Approved
LCD for Blood Glucose Monitoring in a Skilled Nursing Facility (SNF) (L34834) Contractor Name: Novitas Solutions, Inc. Contractor Number: 12502 Contractor Type: MAC B LCD ID Number: L34834 Status: A-Approved
More informationThe Effect of Alcohol Prep Pads and Blood Drop Number On Capillary Blood Glucose Values
University of New Hampshire University of New Hampshire Scholars' Repository Honors Theses and Capstones Student Scholarship Spring 2017 The Effect of Alcohol Prep Pads and Blood Drop Number On Capillary
More informationQuick Reference Guide
FLASH GLUCOSE MONITORING SYSTEM Quick Reference Guide IMPORTANT USER INFORMATION Before you use your System, review all the product instructions and the Interactive Tutorial. The Quick Reference Guide
More informationEvaluating Once- and Twice-Daily Self- Monitored Blood Glucose Testing Strategies for Stable Insulin-Treated Patients With Type 2 Diabetes
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Evaluating Once- and Twice-Daily Self- Monitored Blood Glucose Testing Strategies for Stable Insulin-Treated Patients With
More informationPoint of Care (POC) Glucose Testing Revised on: December, 2018 Reference: Policy LAB 23-A; Point of Care Nova Stat Strip Glucose Meter
Point of Care (POC) Glucose Testing Revised on: December, 2018 Reference: Policy LAB 23-A; Point of Care Nova Stat Strip Glucose Meter The Nova Stat Strip Blood Glucose meter is UHB s approved Glucometer
More informationKINGSTON DEMENTIA RATING SCALE
KINGSTON DEMENTIA RATING SCALE -KDRS- I-RatingForm II - Instruction Manual III - Score Interpretation IV - Chart Summary Copyright 2015 R.W. Hopkins, L. Kilik Semoprs Mental Health, Providence Care, Mental
More informationQuick Reference Guide
FLASH GLUCOSE MONITORING SYSTEM Quick Reference Guide IMPORTANT USER INFORMATION Before you use your System, review all the product instructions and the Interactive Tutorial. The Quick Reference Guide
More informationReport Reference Guide. THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1
Report Reference Guide THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1 How to use this guide Each type of CareLink report and its components are described in the following sections.
More informationOneTouch Reveal Web Application. User Manual for Healthcare Professionals Instructions for Use
OneTouch Reveal Web Application User Manual for Healthcare Professionals Instructions for Use Contents 2 Contents Chapter 1: Introduction...4 Product Overview...4 Intended Use...4 System Requirements...
More informationGreat Lakes Partners for Patients: Hospital Improvement Innovation Network - Encyclopedia of Measures Frequently Asked Questions
Great Lakes Partners for Patients: Hospital Improvement Innovation Network - Encyclopedia of Measures Frequently Asked Questions Contents Great Lakes Partners for Patients: Hospital Improvement Innovation
More informationReport Reference Guide
Report Reference Guide How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used to generate the sample reports was from sample patient
More informationFaculty. Disclosures. Prescribing. A Multidisciplinary Approach to Preventing Medication Errors Associated with Insulin Therapy. Learning Objectives
A Multidisciplinary Approach to Preventing Medication Errors Associated with Insulin Therapy Faculty Matthew Grissinger, RPh, FISMP, FASCP Director, Error Reporting Programs Institute for Safe Medication
More information32 CFR (a)(4), (a)(6)(iii), and (a)(6)(iv)
CHAPTER 15 SECTION 1 ISSUE DATE: November 6, 2007 AUTHORITY: 32 CFR 199.14(a)(4), (a)(6)(iii), and (a)(6)(iv) I. APPLICABILITY This policy is mandatory for the reimbursement of services provided either
More informationBlood Glucose Metabolism Instructor s Guide
Blood Glucose Metabolism Instructor s Guide Time to Complete Recommended time to complete 45-60 minutes Prior Knowledge Students should have a basic understanding of the function of glucose in normal metabolism.
More informationPerformance-powered. The OneTouch. Ping insulin pump and meter-remote.
Performance-powered. The OneTouch Ping insulin pump and meter-remote. I We don t just deliver insulin. We deliver outstanding clinical performance. P36337_OTP_DetAid_OmniPodUpdate_r12.indd 1 OneTouch Ping.
More informationQuick Reference Guide
FLASH GLUCOSE MONITORING SYSTEM Quick Reference Guide FreeStyle LibreLink app A FreeStyle Libre product IMPORTANT USER INFORMATION Before you use your System, review all the product instructions and the
More informationMass Spectrometry Made Simple for Clinical Diagnostic Labs
Mass Spectrometry Made Simple for Clinical Diagnostic Labs The SCIEX Topaz System with FDA-Cleared Topaz Vitamin D 200M Assay Kit Mass Spectrometry Made Simple SCIEX Topaz System for Clinical Diagnostics
More informationHyperglycemia Procedure: Management and Treatment Adult Patients
Approved by: Chief Operating Officer; and Chief Medical Officer Hyperglycemia Procedure: Management and Treatment Corporate Policy & Procedures Manual Number: VII-B-465 Date Approved January 23, 2018 Date
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE GLYCEMIC MANAGEMENT - ADULT SCOPE Provincial: Acute Care APPROVAL AUTHORITY Clinical Operations Executive Committee SPONSOR Diabetes, Obesity & Nutrition Strategic Clinical Network PARENT DOCUMENT
More informationProcess or performance improvement is often discussed
Process Improvement in Transfusion Medicine Ongoing efforts to decrease costs in the clinical laboratory make continuous process improvement especially important in difficult economic times. Process improvement
More informationRelationship between glucose meter error and glycemic control efficacy
Relationship between glucose meter error and glycemic control efficacy Brad S. Karon, M.D., Ph.D. Professor of Laboratory Medicine and Pathology Department of Laboratory Medicine and Pathology Mayo Clinic
More informationTHE POTENTIAL IMPACT OF VITALSTIM THERAPY ON HEALTHCARE COSTS: A White PaperVitalStim Therapy has significant
Dysphagia THE POTENTIAL IMPACT OF VITALSTIM THERAPY ON HEALTHCARE COSTS: A White PaperVitalStim Therapy has significant Contents potential to dramatically impact the health care costs arising from oropharyngeal
More informationMeeting the Challenge of Inpatient Glycemic Management in the Non-Critical Care Setting
Meeting the Challenge of Inpatient Glycemic Management in the Non-Critical Care Setting Jane Jeffrie Seley, DNP, MPH, GNP, BC-ADM, CDE, CDTC, FAAN, FAADE Diabetes Nurse Practitioner, Inpatient Diabetes
More informationPATHOLOGICAL VIEW FUNCTIONAL VIEW
Introduction Most of us are using the conventional laboratory reference ranges for our blood chemistry and CBC interpretation. For many practitioners blood chemistry and CBC analysis is a matter of comparing
More informationTopics in Inpatient Glycemic Control
Topics in Inpatient Glycemic Control Jane Jeffrie Seley DNP MPH MSN GNP BC-ADM CDE CDTC FAADE FAAN Diabetes Nurse Practitioner Program Manager, Inpatient Glycemic Control Program NewYork-Presbyterian/
More informationTitle: DreamTel; Diabetes Risk Evaluation and Management Tele-monitoring Study
Author's response to reviews Title: DreamTel; Diabetes Risk Evaluation and Management Tele-monitoring Study Authors: Sheldon Tobe (sheldon.tobe@sunnybrook.ca) Joan Wentworth (jwentworth@miwayawinhealth.org)
More informationBasal Bolus Insulin Therapy Frequently Asked Questions
1. What is Basal Bolus Insulin Therapy (BBIT)? 2. What evidence supports the use of subcutaneous Basal Bolus Insulin Therapy? 3. Does Basal Bolus Insulin Therapy apply to all patients? 4. What s wrong
More informationFigure 2.1: Glucose meter
CHAPTER TWO: MONITORING TECHNOLOGIES 2.1 Introduction Glucose monitoring is a method of self-testing glucose (blood sugar) levels for the management of diabetes. Traditionally, it involves pricking the
More informationLIBERTYHEALTH. Jersey City Medical Center Department of Patient Care Services. Approved by Policy Committee:
LIBERTYHEALTH Jersey City Medical Center Department of Patient Care Services Guidelines: CRITICAL CARE INSULIN PROTOCOL (MICU/SICU, CCU, ED) Developed by: Pharmacy Dept Approved by: Rita Smith, DNP Senior
More informationJanuary Testing Delays and Spurious Results Caused by Improper Specimen Collection
January 2011 Testing Delays and Spurious Results Caused by Improper Specimen Collection Lauren Anthony, MD, MT(ASCP)SBB Medical Director, Allina Medical Laboratories Collecting a specimen may seem routine,
More informationGreat Lakes Partners for Patients: Hospital Improvement Innovation Network - Encyclopedia of Measures Frequently Asked Questions
Great Lakes Partners for Patients: Hospital Improvement Innovation Network - Encyclopedia of Measures Frequently Asked Questions Contents Great Lakes Partners for Patients: Hospital Improvement Innovation
More informationDiagnosis and Management of Type 2 Diabetes Mellitus in Adults
Quality Improvement Support: Diagnosis and Management of Type 2 Diabetes Mellitus in Adults The Aims and Measures section is intended to provide guideline users with a menu of measures for multiple purposes,
More informationPARENT PACKET - DIABETES
School Year: Lexington-Fayette County Health Department SCHOOL HEALTH DIVISION 650 Newtown Pike Lexington, Kentucky 40508-1197 (859) 288-2314 (859) 288-2313 Fax PARENT PACKET - DIABETES Dear Parent/Guardian:
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationMultiple studies are available concerning the use of
SPECIAL ARTICLE Evaluation of the Biosite Ò Quantitative Whole Blood D-dimer Assay and Comparison With the biomérieux VIDAS Ò D-dimer Exclusion Test Validation and Utility For Use in the Central Laboratory
More informationREVIEW AND FREQUENTLY ASKED QUESTIONS (FAQ) 8/5/2015. Outline. Navigating the DSMT Reimbursement Maze in Todays Changing Environment
Patty Telgener RN, MBA, CPC VP of Reimbursement Emerson Consultants Navigating the DSMT Reimbursement Maze in Todays Changing Environment Patty Telgener, RN, MBA, CPC VP of Reimbursement Emerson Consultants
More informationHospitalization, Psychiatric, Adult
Hospitalization, Psychiatric, Adult Criteria for Admission The specified requirements for severity of need and intensity and quality of service must be met to satisfy the criteria for admission. I. Admission
More informationState of California Health and Human Services Agency Department of Health Care Services
State of California Health and Human Services Agency Department of Health Care Services JENNIFER KENT Director EDMOND G. BROWN JR Governor DATE: N.L.: 03-0317 Index: Benefits TO: ALL COUNTY CALIFORNIA
More informationChapter 2: Identification and Care of Patients with CKD
Chapter 2: Identification and Care of Patients with CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationADMELOG, NOVOLIN, NOVOLOG, and FIASP
ADMELOG, NOVOLIN, NOVOLOG, and FIASP Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationProvincial Clinical Knowledge Topic Insulin Pump Therapy, Pediatric and Adult Acute Care V 1.0
Provincial Clinical Knowledge Topic Insulin Pump Therapy, Pediatric and Adult Acute Care V 1.0 Copyright: 2018, Alberta Health Services. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives
More informationScope of Practice for the Diagnostic Ultrasound Professional
Scope of Practice for the Diagnostic Ultrasound Professional Copyright 1993-2000 Society of Diagnostic Medical Sonographers, Dallas, Texas USA: All Rights Reserved Worldwide. Organizations which endorse
More informationIntroduction. Methods
A New Perspective On A Difficult Discharge: Ensuring the newly diagnosed diabetic patient gets the proper prescriptions when it s time to go home. Ashley Carter, PGY 3 Introduction A hospitalized patient
More informationAdvances in Diabetes Care Technologies
Advances in Diabetes Care Technologies 1979 2015 Introduction Roughly 20% to 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the U.S. FDA
More informationNOT-SO-SWEET! THE STRAIGHT SCOOP ON DIABETES IN THE HOSPITAL SETTING
Sharp HealthCare s 2016 Diabetes Conference November 11, 2016 NOT-SO-SWEET! THE STRAIGHT SCOOP ON DIABETES IN THE HOSPITAL SETTING Tamara Swigert, MSN, RN, CDE Speaker Disclosure Tammy Swigert has no conflicts
More information